HONG KONG, April 27, 2026 /PRNewswire/ — Hosted by the World Internet Conference (WIC), organised by the Hong Kong Special Administrative Region (HKSAR) Government, and co-organised by the Innovation, Technology and Industry Bureau, the 2026 WIC Asia-Pacific Summit was held in Hong Kong on 13-14 April 2026 and concluded successfully. The two-day international flagship event brought together around 1000 global innovation and technology (I&T) stakeholders, including government and business leaders, representatives from international organisations, experts and scholars from over 50 countries and regions. The Summit further deepened regional digital cooperation, showcased Hong Kong’s progress and advantages in driving digital transformation and AI governance, and reinforced its position as an international I&T centre and a two-way platform connecting the country and the world.
The Summit focused on a range of frontier technology topics, including AI security and governance which is of great concern to the industry. Speaking at the related forum, the Acting Commissioner for Digital Policy, Mr. Daniel Cheung, outlined Hong Kong’s approach to balancing AI development with regulated use, which is in line with the National 15th Five-Year Plan. He added that the HKSAR Government is accelerating AI industrialisation while fostering a trusted ecosystem for safe applications.
Opening ceremony of the World Internet Conference Asia-Pacific Summit 2026.
Mr. Cheung emphasised that the upcoming Hong Kong Artificial Intelligence Research and Development Institute (AIRDI) would play a crucial role. He said, “The AIRDI will provide safety assessments and compliance consulting services, enabling enterprises to train and test AI models in secure and standardised environments that meet international benchmarks. The AIRDI will also foster cross-sector and inter-regional collaboration on AI standardisation. We encourage the public and enterprises to embrace AI with confidence and security, and work together to build a secure, open and responsible AI ecosystem.”
Acting Commissioner for Digital Policy, Mr Daniel Cheung, addresses the World Internet Conference Asia-Pacific Summit 2026.
Mr. John Hoffman, CEO of GSMA Ltd, highly commended Hong Kong’s advantages demonstrated as the host of the Summit. He remarked, “Hong Kong has been the epicentre of East meets West. It plays a pivotal role in digital transformation and, together with its strengths in mobile technologies is critical to global innovation. Also, the Summit provides great opportunities to showcase innovation and digital transformation along with the mobile ecosystem here in Hong Kong.”
CEO of GSMA Ltd, Mr John Hoffman, attends the World Internet Conference Asia-Pacific Summit 2026.
Mr. Leonard Chan, Founding Chairman of the Hong Kong Innovative Technology Development Association, attended the Summit for the second consecutive year and highlighted Hong Kong’s strategic advantages. He noted, “Hong Kong is truly one of a kind as a platform that bridges international practices and helps leading Mainland enterprises go global. This is my second time attending the WIC Asia-Pacific Summit. As with last year, the Summit is an excellent platform that brings together global experts, providing business and academic communities with opportunities for in-depth exchanges. The successful hosting of the Summit is a testament to Hong Kong’s unique position as an international I&T centre.”
Founding Chairman of the Hong Kong Innovative Technology Development Association, Mr Leonard Chan, attends the World Internet Conference Asia-Pacific Summit 2026.
The Summit successfully created a high-level platform for international exchange through the Ministerial Meeting, the Government-Enterprise Dialogue, various thematic forums and technology showcases. Moving forward, the HKSAR Government will continue to leverage its distinctive advantages of having strong support from the motherland and close connection with the world to accelerate Hong Kong’s development as an international I&T centre and contribute towards building a community with a shared future in cyberspace.
Teaser Visual and Trailer Unveiled; World Tour Confirmed, Culminating in Japan with the First Full Screening of Episode 1
Special Illustration and Comments Released from Original Author Takeru Hokazono, Director Tetsuya Takeuchi, Character Designer Keigo Sasaki, and Taihi Kimura (Voice of Chihiro Rokuhira)
TOKYO, April 27, 2026 /PRNewswire/ — CyberAgent, Inc., as a co-chief production partner with Shochiku Co., Ltd., is pleased to announce that anime adaptation of Takeru Hokazono’s Kagurabachi will begin broadcasting and streaming in April 2027.
A next-generation flagship title from Weekly Shonen Jump, Kagurabachi (Original Author: Takeru Hokazono) has officially been confirmed for a TV anime adaptation. The original manga is currently serialized in Shueisha’s Weekly Shonen Jump and will surpass a cumulative circulation of 4 million copies (including digital editions) with the release of Volume 11 in Japan on Friday, May 1. Produced by Cypic(Umamusume: Cinderella Gray, The Summer Hikaru Died), the anime series is scheduled to begin broadcasting and streaming in April 2027.
To mark the announcement, a teaser visual and trailer have been released alongside a special commemorative illustration and comment from the original author, Takeru Hokazono, as well as comments from Director Tetsuya Takeuchi, Character Designer Keigo Sasaki, and lead voice actor Taihi Kimura, who voices the protagonist, Chihiro Rokuhira.
Furthermore, the Kagurabachi World Tour has officially been confirmed. It will feature a screening of the first 20 minutes of Episode 1 and culminate in Japan with the world’s first full-length screening of Episode 1.
Kagurabachi is set to begin broadcasting and streaming globally in April 2027, in partnership with MUSE, and SMG HOLDINGS, among others.
Introduction A single stroke opens a new era, cutting a path from Japan to the world— Weekly Shonen Jump’s Neo-Japanese Sword Action series begins here!
From day one, the Kagurabachi manga has captivated fans, weaving a blood-soaked tale of revenge through breathtaking sword-fight sequences.
And now, known for its uncompromising quality, animation studio Cypic brings the story to life with jaw-dropping visuals!
Story Flames of resolve, kindled by hatred.
Chihiro Rokuhira is a boy who aspires to become a swordsmith, and took daily training under his father Kunishige, a renowned swordsmith. Their days, once filled with laughter, are brutally torn apart by an attack from the mysterious sorcerer organization, the Hishaku.
What is stolen from them are the six Enchanted Blades—swords of immense power capable of shaping the fate of the nation—and the gentle, warm life they once shared.
From that day on, everything changed. In a world engulfed in darkness, Chihiro takes up Enten, the seventh Enchanted Blade left behind by his father, and sets out on a blood-soaked path of revenge.
Teaser Visual & Trailer The newly released teaser visual captures Chihiro Rokuhira poised with his Enchanted Blade, fixing his gaze forward with fierce determination. In the background, three goldfish—Aka, Kuro, and Nishiki—dance through the air. The composition masterfully blends stillness and motion, signaling the beginning of an epic saga. The teaser trailer opens with the forge where swords are made, highlighting one of the series’ central themes: katana. Set in a Japan where modern landscapes and timeless Japanese aesthetics converge, the trailer vividly brings to life the opening of Chihiro’s revenge story. Its weighty atmosphere and palpable tension draw viewers into the singular world of Kagurabachi.
Cast & World Tour Information Rising star Taihi Kimura, winner of the 2025 Seiyu Awards for Best New Actor, has been cast as the story’s protagonist, Chihiro Rokuhira.
The Kagurabachi World Tour is set to begin in summer 2026. As part of the tour, exclusive 20-minute preview screenings of Episode 1 will be held at venues across the world. The tour will culminate in Japan in spring 2027 with the first full-length screening of Episode 1 ahead of its official broadcast. Further details regarding dates and venues will be announced at a later date.
Comments from Takeru Hokazono, Tetsuya Takeuchi, Keigo Sasaki, and Taihi Kimura
Takeru Hokazono (Original Author) Profile: His first manga was the one-shot Enten, which won the 100th Tezuka Award in 2020 and was published in Jump GIGA’s Spring 2021 issue. He is currently serializing Kagurabachi in Shueisha’s Weekly Shonen Jump.
Comment from Takeru Hokazono: “You know the Rock Lee vs. Gaara fight in Naruto? The manga version is great of course, but isn’t the anime’s version just incredibly cool? Well, the very person who brought that scene to life is our director! Woo!
The staff is full of amazing people who really know the manga inside and out. I can’t wait to see how the animation turns out! Definitely a must-watch!”
Tetsuya Takeuchi (Director) Profile: His recent works include Sword Art Online II (Action Animation Director), Lycoris Recoil (Storyboards, Episode Director, Animation Director, Key Animation) and Heavenly Delusion (Battle Scene Storyboards, Episode Director, Animation Director), among others.
Comment from Tetsuya Takeuchi: “Who would’ve thought that I’d be directing a popular Shonen Jump anime after working as a key animator on Naruto back when I was just a newbie… you really never know what life has in store.
When you think of Kagurabachi, you think of swords! And more swords! Plus cool characters and intense drama!
I’ll work hard to capture all those elements and aim to make a show that both long-time fans of the manga and first-time viewers alike can enjoy!
There’s a lot of pressure!”
Keigo Sasaki (Character Design) Profile: His recent works include Blue Exorcist and The Seven Deadly Sins, among others.
Comment from Keigo Sasaki: “Hokazono-sensei’s art style is really cool, and I couldn’t wait to see his drawings come to life! I jumped into the design process with nothing but that feeling in mind, but it’s been an uphill battle.
It’s hard… but when I manage to draw something well, it makes me that much happier! The staff and I are working hard every day, and I feel so lucky to be able to participate in this project.
I’ll do my absolute best so that everyone can enjoy the anime.”
Taihi Kimura (Voice of Chihiro Rokuhira) Profile: Affiliated with KEN PRODUCTION. Major roles include Takeshi Narihira in Yin-Yang Kaiten Re:Birth, Adam Krensh in The Beginning After the End, and Leo in TO BE HERO X, among others.
Character Introduction of Chihiro Rokuhira A quiet boy who sets out on a journey to avenge his father, who was killed by the Hishaku, and to recover the six stolen Enchanted Blades. With the remaining seventh Enchanted Blade in hand, he walks a blood-soaked path.
Comment from Taihi Kimura: “I’m Taihi Kimura, and I’ll be voicing Chihiro Rokuhira!
I’m truly grateful for this opportunity to voice the protagonist of Kagurabachi—an incredible series loved by fans all over the world.
A katana is forged and refined through the art of “tanren,” gaining its ultimate strength through the repeated folding of steel.
Chihiro is a quiet young man, but deep in his heart he carries a conviction as unyielding as a sword.
I’m going to give this role my absolute all and pour my heart and soul into it so that Chihiro’s unwavering resolve truly resonates with everyone.
Thank you for your support!”
Follow & Repost Campaign Now Underway! To celebrate the announcement of the anime adaptation, a Follow & Repost campaign is currently running on the official X. Ten lucky winners will be selected by lottery to receive an exclusive teaser visual poster (not for sale). Be sure to check it out!
About KAGURABACHI Broadcasting and Streaming Information April 2027 MUSE, and SMG HOLDINGS, among others
Staff Original Work: “Kagurabachi” by Takeru Hokazono (Serialized in Shueisha’s Weekly Shonen Jump) Director: Tetsuya Takeuchi Character Design: Keigo Sasaki Production: Cypic Production Committee Leads: Shochiku & CyberAgent
Original Work Title: Kagurabachi Author: Takeru Hokazono Previously Published: Available online on MANGA Plus by SHUEISHA (Chapters 1-17 are currently available for free until May 25 for a limited time) and published in print and digital by Viz Media (English Version).
*Copyrights must be indicated when posting or using the images/materials *Single space is needed between “Takeru” and “Hokazono,” and between “Project” and “Kagurabachi.” *No space needed after “/(slash)” and “,(comma).”
Seasoned finance executive combines dual expertise as both technology investor and CFO of fast-growth AI companies
LONDON, April 27, 2026 /PRNewswire/ — IFS, the world’s leading provider of Industrial AI software, today announces the appointment of Ryan Courson as Chief Financial Officer (CFO). Courson joins IFS at a moment of considerable momentum, as the company continues to set the pace for Industrial AI adoption at enterprise scale, and as demand for IFS.ai capabilities accelerate across every region and industry it serves.
IFS enters this next chapter of growth from a position of market-defining strength. The company’s Q1 2026 financial results – reporting 25% Annual Recurring Revenue (ARR) growth and a Net Retention Rate (NRR) of 114% – cement IFS as the only Industrial AI company operating at significant global scale and sustaining growth at this level.
Courson brings a rare combination of operating and investing experience. He has served as CFO at multiple fast-growth, AI-powered technology companies; while also serving as public company CFO at NYSE-listed Atlas Corp. (NYSE: ATCO), a global asset manager with a diversified portfolio spanning maritime, energy, and infrastructure. He began his career as a technology and software investor at Alpha Wave Global, Teton Capital, and Berkshire Hathaway.
Mark Moffat, CEO, IFS, said: “IFS is executing at a level that very few software businesses in the world can match right now. Sustaining that trajectory as we scale requires financial leadership of the very highest caliber. Ryan has built and led financial organizations inside fast-growth AI companies, he understands markets and capital as a sophisticated investor, and he has operated at the level of a publicly listed company. That combination is powerful as IFS drives the next phase of our growth. I am delighted to welcome him to the team.”
Ryan Courson, CFO, IFS, said: “IFS sits at a rare intersection of category leadership and proven performance, with significant runway ahead. What stands out is not just the growth, but its quality and durability at scale. Industrial AI is becoming mission-critical for global enterprises, and IFS is defining that shift. My focus is to support the next phase of growth by strengthening financial discipline, capital allocation, and operating rigor. I’m honored and excited to join Mark and the team at this important moment.”
Courson joins IFS from Kaseya, where he served as COO and CFO. He previously held CFO roles at Cornerstone OnDemand and EagleView. He is also an Adjunct Professor at Washington University in St. Louis’s Olin Business School, where he teaches Investing, and holds a Bachelor of Science in Business Administration from the university.
Courson succeeds Matthias Heiden who leaves IFS in Q2. Moffat added: “I would like to recognize the contribution of Matthias over the last three years. His focus and leadership have significantly helped drive IFS’s growth and we wish him the very best for the future.”
IFS Press Contacts:
EUROPE / MEA / APJ: Adam Gillbe IFS, Director of Corporate & Executive Communications Email: adam.gillbe@ifs.com
NORTH AMERICA / LATAM: Mairi Morgan IFS, Director of Corporate & Executive Communications Email: mairi.morgan@ifs.com
Saskatoon, Saskatchewan – Newsfile Corp. – April 27, 2026 – Buffalo Potash Corporation(TSXV: BUFF) (OTCQB: BLPTF) (the “Company” or “Buffalo“) is pleased to announce the completion of a Preliminary Economic Assessment (“PEA“) and concurrent release of its maiden 43-101 Mineral Resource Estimate for its 100%-owned Disley Potash Project (the “Disley Project“), located in Saskatchewan, Canada.
The PEA has been filed and can be found under the Company’s profile on SEDAR+ (www.sedarplus.ca) and on the Company’s website (www.buffalopotash.ca).
PEA & Mineral Resource Estimate Highlights
Total production of 1,000,000 tonnes per annum (TPA) of K62 granular-grade Muriate of Potash (MOP) and 125,000 TPA of K62 soluble grade MOP
After-tax NPV(1)(8) of US$1.1B and IRR(1) of 30%
US$639M initial CAPEX estimate, including US$128M in contingency
Estimated US$55/t MOP OPEX (Table 4)
Measured and indicated tonnage of 1,671.5 million metric tonnes at an average grade of 34.8% KCl, yielding 582 million tonnes of KCl
Over 50 years of mine life at 1,125,000 TPA based on current resource estimate (Table 2)(2)
The advancement of a Feasibility Study (“FS“) for Disley East and Disley West (the “HLD Mines“) will run concurrent with Initial Production Module (“IPM“) construction, with FS completion representing the key decision gate for proceeding to construction of Disley East and Disley West(3)
(2) Based on Measured and Indicated resource estimate of 582Mt at 34.8% KCl. (3) The PEA does not constitute a feasibility study and does not demonstrate economic viability
Mr. Steve Halabura P.Geo., Buffalo Chief Executive Officer, commented: “Since founding Buffalo Potash in 2018, the team and I have invested years of disciplined work — geological, technical, and strategic — to systematically unlock the potential of modular selective solution potash mining in Saskatchewan, the key being Buffalo’s Disley Project. Having spent my career working in Saskatchewan potash, I had a strong conviction from the beginning that Disley had a substantial resource endowment, and this Mineral Resource Estimate confirms exactly that. The PEA illustrates both low capex per tonne and operating cost per tonne, as well as setting a new environmental standard for how potash production should look in the 21st century — no tailings stored on surface and minimal freshwater usage.”
Mr. Halabura continued: “The team and I believe the Disley Project represents the next generation of Saskatchewan potash solution mining and are excited to begin development of the Initial Production Module, which will be the first leg of this buildout and is expected to bring soluble-grade potash production online within the next 12 months. During the development of the Initial Production Module, we will also test our patent-pending Vortex Crystallizer, alongside an industry standard crystallizer, which has the potential to significantly reduce the capex of the Initial Production Module and further potential build-outs. With global attention turning to the security of critical supply chains, the urgency to bring reliable, jurisdiction-stable potash production online has never been greater. This is a proud moment for our team, our shareholders, and the stakeholders that have supported us along the way — and we are just getting started.”
Table 1: PEA Summary
Line Item
Units
Total Project
Production Rate MOP
TPA
1,000,000
Production Rate Soluble Grade
TPA
125,000
Total Initial CAPEX
US$ million
639
CAPEX per Tonne Capacity
US$/tonne
568
Average Unit OPEX
US$/tonne
55
MOP Price (25-year avg.)
US$/tonne
393.6(4)
Soluble Grade Price (25-year avg.)
US$/tonne
373.6(5)
Pre-Tax NPV(1) (8%)
US$ million
1,534.67
Pre-Tax IRR(1)
%
35
Post-Tax NPV(1) (8%)
US$ million
1,085.47
Post-Tax IRR(1)
%
30
Steady-State Annual Revenue
US$ million
442.5
Steady-State Annual EBITDA
US$ million
251.0
(4) LoM average price of Granular MOP, produced by Disley East and Disley West (5) LoM average price of Soluble Grade MOP, produced by IPM
The PEA is preliminary in nature and includes inferred mineral resources, which are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. There is no certainty that the PEA will be realized.
PEA & Mineral Resource Estimate Overview
The PEA was prepared by Micon International Co Limited (“Micon“) in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects and evaluates the development of the Disley Project as a phased potash solution mining operation. The PEA has an effective date of April 15, 2026 and is based on a Mineral Resource Estimate (“MRE“) developed concurrently by Micon with an effective date of April 15, 2026, incorporating historical assay data from legacy drilling programs as well as results from Buffalo Potash’s 2026 confirmation drill program. The PEA contemplates a phased development approach across three production facilities on the Disley property:
The Initial Production Module (“IPM”) – is a low-capital entry point designed to bring 125,000 tonnes per year of soluble grade MOP to market;
Disley East – a full-scale HLD Mine on the east segment of the Disley Project, with a production capacity of 500,000 tonnes per year of granular MOP; and
Disley West – a full-scale HLD Mine on the west segment of the Disley Project, with a production capacity of 500,000 tonnes per year of granular MOP.
Successful construction of the IPM is anticipated to provide technical data used in the completion of the concurrent FS and would, subject to the results from the FS and a positive construction decision, be followed by the potential concurrent development of the Disley East and Disley West HLD solution mines. If fully developed, the Disley Project is designed to have the capacity to produce 1,000,000 TPA of granular MOP and 125,000 TPA of soluble grade MOP (“Full Production Capacity“).
The MRE indicates a resource base that substantially exceeds the project’s current design requirements, which, if successfully developed, would position the Disley Project as a long-life asset. This is consistent with the generational mine lifecycles typically associated with Saskatchewan potash operations, though there is no certainty that resources will be converted to reserves or that any particular mine life will be achieved.
Table 2: Mineral Resource Estimate
Category
Tonnage (Mt)
Avg KCl Grade
Avg K2O Grade
KCl (Mt)
K2O (Mt)
Measured
399.7
34.82%
22.00%
139.2
87.9
Indicated
1,267.4
34.84%
22.01%
441.5
278.9
Inferred
2,663.2
34.96%
22.08%
930.9
588.1
Table 2 Notes:
The effective date of this MRE is April 15, 2026.
Dr. Ryan Langdon, Ph.D, CGeol, of Micon is the QP responsible for this MRE.
The MRE has been classified in the Measured, Indicated and Inferred categories.
An average specific gravity (SG) value of 2.08 g/cm3 was used.
Conversion between KCl and K2O was made using the formula KCl = K2O * 1.583
The MRE used economic assumptions for HLD mining. A deduction was made to account for the presence of mining anomalies not detected by existing drill holes and seismic lines. The values used are 5% for Measured, 9% for Indicated and 25% for Inferred.
The block model supporting the resource is orthogonal and has a block size of 50 m x 50 m x 0.9 m.
The mineral resources described above have been prepared in accordance with the current Canadian Institute of Mining, Metallurgy and Petroleum Standards and Practices.
Numbers have been rounded to the nearest million tonnes. Differences may occur in totals due to rounding.
Mineral Resources are not Mineral Reserves as they do not have demonstrated economic viability. The quantity and grade of reported Inferred Mineral Resources are uncertain in nature and there has been insufficient exploration; however, it is reasonably expected that a significant portion of Inferred Mineral Resources could be upgraded into Indicated Mineral Resources with further exploration.
Micon’s QP has not identified any legal, political, environmental, or other factors that could materially affect the potential development of the mineral resource estimate.
Figure 1: Core Samples from the 7-10 Hole on the Disley Project
Buffalo intends to develop the Project using solution mining, a well-established approach that has been successfully deployed across Saskatchewan for more than 50 years. Solution mining is widely recognized as a reliable and efficient technique for extracting potash from laterally continuous deposits, notably used at both neighboring properties of the Disley Project — the K+S Bethune mine and the Mosaic Belle Plaine mine.
Building on this proven foundation, Buffalo holds a patent on an enhanced solution mining approach known as Horizontal-Line-Drive Selective Solution Mining (“HLD Mining“), which is the installation of commercially proven oil and gas injection systems within horizontal wells. This method is designed to optimize efficiency, reduce overall capital intensity, and significantly limit freshwater requirements, while remaining grounded in the principles of traditional solution mining.
Following underground dissolution, potash-rich brine is recovered to surface and processed through crystallization, drying, and compaction to produce a finished potash product ready for local delivery or export via existing road and rail infrastructure that currently runs adjacent to the Disley Property.
Initial Capital Expenditure (CAPEX)
The initial capital cost estimate has been prepared in line with the Class 4 definition outlined by AACE International standards, with a contingency of 25% applied to the IPM, Disley East, and Disley West components.
Mechanical equipment represents the largest component of initial capital expenditure at approximately 38% of Total Project initial CAPEX. For Disley East and Disley West, the mechanical scope encompasses the full processing train required to produce export-grade granular MOP, including crystallization, debrining and drying, compaction and glazing, soluble product screening, and product storage and loading. For the IPM, the mechanical scope includes a crystallizer, pumps, tanks, pipework, centrifuge, dryer, and baghouse. Total initial capital expenditure across all three facilities is US$639 million, as summarized in the table below.
Table 3: Initial CAPEX Summary
Description
IPM
Disley East
Disley West
Total Project
(US$ million)
(US$ million)
(US$ million)
(US$ million)
Site Works
0.7
11.3
11.3
23.3
Concrete
–
5.6
5.6
11.2
Structural Steel
1.2
9.3
9.3
19.9
Mechanical
15.1
113.3
113.3
241.7
Piping
0.2
14.9
14.9
30.0
Electrical
–
15.0
15.0
29.9
Instrumentation
0.1
2.9
2.9
5.9
Architecture
0.0
19.6
19.6
39.2
Minor Mechanical
4.7
2.4
2.4
9.4
General Construction
1.4
13.3
13.3
28.0
Indirects
–
36.1
36.1
72.3
Contingency
5.8
60.9
60.9
127.7
Total Capital Expenditure(6)
29.2
304.7
304.7
638.6
(6) For modelling purposes, the total capital expenditure estimate for the PEA assumes use of an industry standard crystallizer instead of Buffalo’s patent-pending Vortex Crystallizer.
Sustaining capital of US$483 million (US$17/t MOP) over the life of mine comprises an annual provision of 2% of original fixed plant and surface infrastructure costs, plus US$10/t MOP for the drilling, completion and tie-in of replacement wells — the dominant component of sustaining capital — based on each set of three wells yielding 500,000 tonnes over an approximate 5-year useful life.
Operating Expenses (OPEX)
Buffalo Potash’s estimated operating cost of US$55/t MOP reflects the structural advantages of operating in Saskatchewan, a mature potash jurisdiction with competitive industrial energy rates, an established skilled workforce, and existing road and rail infrastructure adjacent to the Disley Property enabling low-cost delivery to both domestic and export markets. Buffalo management anticipates these fundamentals position the Disley Project to be among the lowest-cost potash producers upon reaching full production.
Table 4: OPEX Summary
Item
Description
1,125,000 TPA
(US$ million)
IPM Contingency
$14.49/t applied to IPM production only
1.8
Wellfield Power
500 Hp at $0.063/kWh
1.8
Processing Power
19,356 Hp at $0.063/kWh
18.0
Drilling
$25,000/day; 45 days/yr
0.1
Pipes, Pumps, Valves
Steaming & general maintenance
0.8
Instrumentation
Monitoring & controls
0.4
Labour
32 staff
7.8
Natural Gas
$386/1000m³ incl. carbon tax
19.6
Maintenance
5% of major equipment capital
5.4
Reagents
Dedust oil & anticake amines
2.0
Water
$2.20/m³; 45 m³/hr
1.3
General & Admin Supervision
Management & safety
1.9
Admin Supplies
Office & admin supplies
0.8
Total Annual OPEX
61.7
OPEX US$/t MOP
55 / tonne
Economic Assumptions
The economic analysis evaluates the Disley Project as a phased development consisting of the IPM to establish early cash flow, followed by the full-scale HLD Mine comprising Disley West and Disley East. The IPM was evaluated as a standalone project, with the HLD Mine (Disley East and Disley West) assessed on an incremental basis and in combination with the IPM as an overall project. A Discounted Cash Flow (“DCF“) model was constructed with the following assumptions:
All costs and revenues are expressed in constant, first quarter 2026 money terms, with no provision for escalation or inflation;
Capital and operating cost estimates denominated in Canadian dollars have been converted to US dollars at an exchange rate of CAD 1.38 per USD;
A discount rate of 8% has been applied on an all-equity basis;
The pre-tax results presented include the Saskatchewan Potash Production Tax (PPT) and royalties but exclude federal and provincial corporate income tax. The after-tax results include corporate income tax (Saskatchewan 12%, Federal 15%);
The IPM ramps up over 3 months at 50% of nominal capacity; Disley West and Disley East have a 6-month ramp-up period at 50% of capacity, with the Disley East being deferred by a 3-month offset from the West Section;
It is assumed the IPM is scheduled to begin construction July 2026 with commercial operations starting January 2027;
It is assumed that a positive construction decision will be reached on Disley West and Disley East. Disley West is scheduled to begin construction July 2027, with operations beginning July 2029. Construction at Disley East is scheduled to be the final facility developed, with construction beginning October 2027 and operations beginning October 2029;
Soluble grade MOP produced by the IPM is sold locally, incurring a transport cost of US$10/t compared to US$43/t for export grade granular MOP railed FOB Vancouver; soluble grade MOP is priced at a US$20/t discount to granular, reflecting a life-of-mine average of US$373.6/t versus US$393.6/t FOB Vancouver;
In addition to MOP, the IPM will produce 50,000 m³ per year of KCl brine that may be attractive to regional oilfield services customers at an average transport cost of US$10/m³;
Payback period is measured from the start of construction to the point at which cumulative cash flow turns positive; and
Although the project’s mine life is anticipated to extend beyond a 25-year time frame, the NPV(1) and IRR(1) calculations reflect a 25-year “LoM” period.
The primary input parameters for the DCF model are outlined in the table below.
Table 5: Summary of Inputs for Economic Analysis
Input Parameters
Unit
Value
Evaluation Base Date – IPM
Date
2026-07-01
Evaluation Base Date – Disley East & Disley West
Date
2027-07-01
Sales: HLD Mine MOP Sales (granular)
TPA
1,000,000
Sales: IPM MOP (soluble)
TPA
125,000
Sales: KCl Brine
m3/yr
50,000
Price: Granular MOP (FOB Vancouver) 25-year average
US$/t
394
Price: Soluble MOP 25-year average
US$/t
374
Price: KCl Brine
US$/m3
43
Transport Costs: Granular MOP
US$/t
43
Transport Costs: Soluble MOP
US$/t
10
Transport Costs: KCl Brine
US$/m3
10
Corporate Tax (Sask. + Canada)
%
27%
Contingency for CAPEX
%
25%
Discount Rate
%
8%
NPV calculation
Years
25
The Disley East and Disley West mines have a start date of construction later than that of the Initial Production Module, and their IRR(1), NPV(1) and Payback periods are all calculated from that later date, while the overall Project results reflect the start date of the IPM. The individual IPM phase has a payback period of 1.1 years, while Disley East and Disley West each respectively have payback periods of 2.9 years. The total Project payback of 4.7 years reflects an earlier calculated start date at the time of first production at the IPM, prior to first production from Disley East and Disley West.
Table 6: Summary of Outputs
Metric
Unit
Total Project
Initial CAPEX
US$ million
639
OPEX
US$
55 / tonne
Pre-Tax NPV(1) (8)
US$ million
1,534
Pre-Tax IRR(1)
%
35%
Post-Tax NPV(1) (8)
US$ million
1,085
Post-Tax IRR(1)
%
30%
The Disley Project
The Disley Project is located approximately 50km northwest of Regina and covers 10,610 hectares (Crown and Freehold mineral rights). The property is situated immediately adjacent to the east of the K+S Bethune potash solution mine and north of the Mosaic Belle Plaine potash solution mine — both of which are amongst the largest producing potash solution mines in the world. In the opinion of management, the Disley Project is in one of the most favorable areas of Saskatchewan for potash solution mining (see Figure 2) as evidenced by the success of these neighboring projects(6).
Figure 2: The Disley Property Situated Amongst Major Potash Solution Mines(7)
Buffalo Potash is an emerging Saskatchewan-based potash developer pursuing a modular approach to selective solution mining through its patented Horizontal Line-Drive (HLD) technology. Buffalo is advancing the Disley Project — located next to several of the most prominent currently producing potash solution mines in the world — with the objective of establishing capital-efficient, lower-impact potash production in one of the world’s leading potash jurisdictions.
Qualified Person
The scientific and technical information contained in this news release has been reviewed and approved by Douglas F. Hambley, PhD, PE, P.Eng., PG, an independent consultant of the Company and Qualified Person as defined under NI 43-101 Guidelines. Dr. Hambley is a globally recognized expert in potash geology and mine development and has assisted Micon in their preparation of the MRE and PEA.
All related and pertinent information has also been reviewed for this news release by Jared Galenzoski, P.Geo, FIMMM as an independent consultant and Qualified Person as defined under NI 43-101. Mr. Galenzoski is also an expert in several potash-related fields and has assisted Micon in their preparation of the MRE and PEA.
Technical Report and Qualified Persons
For more information in respect of the Disley Project, including with respect to key assumptions, parameters, and methods used to estimate the MRE, data validation and QA/QC procedures, and the basis, qualifications and assumptions for the PEA, please refer to the entirety of the Technical Report prepared by Ryan Langdon, PhD, P.Geol.; Jack Nagy, PEng; Christopher Jacobs, CEng., MIMMM; and Richard Thompson, CEng, MiChemE. Each of the aforementioned persons is considered a “Qualified Person” for the purposes of NI 43-101 and has reviewed and approved the scientific and technical disclosure contained in this news release. No limitations were imposed on their verification process. Readers are cautioned to review the entirety of the PEA as it contains additional disclosures material to the matters discussed in this press release.
Notes (7) The K+S Bethune potash solution mine and north of the Mosaic Belle Plaine potash solution mine (together, the “Adjacent Properties“) may each be considered an “adjacent property” (within the meaning of NI 43-101) to the Company’s Disley Project. The Company does not have any interest in either of the Adjacent Properties. The Company believes this context is useful in illustrating the proven endowment of the district, while noting that mineralization on adjacent or nearby properties is not indicative of mineralization on the Company’s Disley Project. There is no guarantee that the Disley Project will yield comparable results to any of these mines.
Contact Steve Halabura, P.Geo. | Chief Executive Officer & Director Email: steve@buffalopotash.ca | Phone: 1-306-220-7715
(1) Non-GAAP Financial Measures
Net Present Value (“NPV“) and internal rate of return (“IRR“) are forward-looking financial measures used by management to evaluate the economic potential of the Disley Project, as estimated in the PEA. These measures do not have standardized definitions under IFRS and may not be comparable to similar measures disclosed by other issuers.
NPV represents the sum of discounted future after-tax cash flows projected over the 25-year evaluation period at a discount rate of 8%, net of initial and sustaining capital expenditures. The most comparable IFRS measure is net income (loss); however, NPV is a forward-looking measure that reflects projected future cash flows and cannot be directly reconciled to historical net income. IRR represents the discount rate at which NPV equals zero across the project’s projected cash flows.
These measures should not be construed as alternatives to net income, comprehensive income, or cash flows from operations as determined in accordance with IFRS. Readers are cautioned that these measures reflect PEA-level estimates and are subject to the risks and uncertainties disclosed under “Forward-Looking Information” below.
Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward-looking information is generally identifiable by the use of words such as “believes,” “may,” “plans,” “will,” “anticipates,” “intends,” “could,” “estimates,” “expects,” “forecasts,” “projects,” “targets,” “schedules,” or similar expressions, and the negative of such expressions.
Forward-looking information in this news release includes, but is not limited to, statements regarding: the results, assumptions, and projections contained in or derived from the PEA and Mineral Resource Estimate for the Disley Project, including projected production rates, capital and operating costs, NPV, IRR, payback periods, and mine life; the anticipated timing and phasing of construction and commercial production for the IPM, Disley East, and Disley West; the Company’s ability to secure permitting, financing, and all necessary regulatory approvals; the anticipated cost and technical performance of the HLD Mining method; expectations regarding MOP and soluble grade potash pricing, transportation costs, and market access; and the Company’s broader development plans and strategy for the Disley Project.
Forward-looking information is based on management’s reasonable assumptions, estimates, analysis, and opinions made in light of its experience and perception of historical trends, current conditions, and expected future developments, as well as other factors that management believes are relevant and reasonable in the circumstances as of the date such statements are made. Key assumptions underlying the forward-looking information include, but are not limited to: the accuracy of the Mineral Resource Estimate and PEA, including geological, engineering, and cost assumptions; no material adverse changes to commodity prices, exchange rates, or tax and royalty regimes; the availability of financing on acceptable terms; the Company’s ability to obtain necessary permits and approvals on anticipated timelines; and the continued availability of equipment, personnel, and infrastructure.
Forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied, including: the inherent uncertainty of PEA-level studies and the possibility that actual capital costs, operating costs, and production rates differ materially from estimates; changes in potash or fertilizer market prices; fluctuations in currency exchange rates, particularly the Canadian dollar relative to the US dollar; the risk that permitting, financing, or regulatory approvals are not obtained on anticipated timelines or at all; risks related to the development, commissioning, and operation of novel mining technology; risks inherent to solution mining operations; and general business, economic, competitive, political, and social risks and uncertainties.
A PEA is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as Mineral Reserves. There is no certainty that the PEA will be realized. Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.
Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended. The forward-looking information contained herein is made as of the date of this news release, and the Company disclaims any obligation to update or revise such information except as required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The issuer is solely responsible for the content of this announcement.
Phase 2 multicenter, open-label study (NCT07499102) will evaluate the safety and clinical efficacy of CK0801 Tregs in transfusion-dependent aplastic anemia.
HOUSTON, April 27, 2026 /PRNewswire/ — Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2 clinical trial, for the treatment of aplastic anemia.
Aplastic anemia, a rare and life-threatening blood disorder, continues to present a significant challenge for thousands of patients who fall outside the reach of current standard treatments. Aplastic Anemia develops because of an autoimmune attack on the bone marrow, due to unchecked immune imbalance, resulting from exposure to radiation, toxic chemicals, certain medications, and specific viral infections, though in many cases the cause remains unknown. Characterized by bone marrow’s failure to produce essential red blood cells, white blood cells, and platelets, the condition can be fatal within just three months if left untreated. While medical advancements such as intensive immunosuppressive therapy and allogeneic bone marrow transplantation have saved many lives, a stark “unmet need” remains, especially for older Americans > 65 years of age, and patients with minority ethnic background who have difficulty finding a matching donor. These patients are often forced into a lifelong cycle of chronic blood and platelet transfusions. This dependency, coupled with frequent hospitalizations due to severe infections, leads to a drastically diminished quality of life.
“The reality for many aplastic anemia patients is a persistent state of medical fragility,” said Simrit Parmar, MD, MSCI, Founder of Cellenkos and Adjunct Faculty at Texas A&M University School of Engineering Medicine (EnMed). “We are seeing a massive gap in care where traditional ‘gold standard’ treatments simply aren’t an option, leaving these individuals in a cycle of supportive care rather than a true recovery.”
About the CK0801 Phase 2 Study
The Phase 2 multicenter, open-label study (NCT07499102) is designed to evaluate the safety and clinical activity of CK0801 in patients with aplastic anemia
Target Population: Adults (≥18 years) with aplastic anemia who have failed at least one prior line of therapy or are intolerant to standard treatments and are dependent on red blood cell and/or platelet transfusions.
Primary Endpoint: 30% reduction in transfusion requirements at Day 180.
How can CK0801 treat Aplastic Anemia?
In aplastic anemia, body’s own regulatory T cells — that normally keep the immune system under check — are often decreased in number and impaired in function, allowing for the un-opposed autoimmune attack on the bone marrow. Derived from healthy, allogeneic, cord blood, CK0801 is manufactured using Cellenkos’ proprietary CRANE® technology to generate “Supercharged Tregs” that can overcome the inflammatory chaos, by driving Four Rs:
Resolve bone marrow inflammation: Decreases harmful monocytes and cytotoxic CD8+ T cells and interrupts the vicious cycle of immune-mediated destruction of hematopoietic stem cells.
Reset Immune system. Support the recovery of the patient’s own regulatory T cell function and retrains them to start working well for long term protection
Restore homeostasis: Foster a protected microenvironment in which stem cells may regenerate and produce healthy blood cells
Reduce transfusion burden: Potentially enable patients to achieve durable transfusion independence in responders.
“FDA clearance to advance CK0801 into the Phase 2 trial is a pivotal milestone for Cellenkos and, more importantly, for patients living with aplastic anemia,” said Tara Sadeghi, Chief Operating Officer, Cellenkos. “Our Phase 1 experience with CK0801, showed a favorable safety profile and early signals of durable clinical activity, with follow-up of up to 3.5 years of transfusion independence in individual patients. We look forward to further evaluating CK0801 as a potentially non-toxic, transformative and curative therapy that can bring meaningful improvements in patient lives”
CK0801 is designed to act, in effect, as an immunological “peacekeeper” — calming the immune attack on the bone marrow and creating conditions intended to support hematopoietic recovery, regardless of the initial trigger of the disease.
CK0801 Phase 1 Trial Outcomes
Phase 1 results for CK0801 in bone marrow failure syndromes were published in NEJM Evidence (2024). In that study of 9 enrolled patients (4 with aplastic anemia, 4 with myelofibrosis, and 1 with hypoplastic myelodysplastic syndrome), CK0801 was administered intravenously through peripheral line, in the outpatient setting, without lymphodepleting chemotherapy or interleukin-2 (IL-2) supplementation. No infusion reactions, no dose-limiting toxicities, and no Grade 3 or 4 severe adverse reactions attributable to CK0801 were reported. Among aplastic anemia patients, at 12 months assessment, 3 of 4 achieved a partial response, and 2 of 3 patients who were transfusion-dependent at baseline achieved durable transfusion independence.
About CK0801
CK0801 is manufactured from a single allogeneic umbilical cord blood unit (CBU) collected and banked from a healthy normal donor who has met FDA requirements for screening and testing for transmissible disease, in compliance with 21 CFR Part 1271, Subpart C. The FDA previously granted Orphan Drug Designation to CK0801 for the treatment of aplastic anemia, reflecting the significant unmet medical need in this patient population. CK0801 remains investigational and has not been approved by the FDA for any indication.
About Cellenkos, Inc.
Cellenkos®, Inc. is a clinical-stage biotechnology company developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies for autoimmune diseases and inflammatory disorders. Cellenkos was granted US patent (US12472182B2) on November 18, 2025, for their technology covering “Compositions comprising regulatory t cells and methods of” producing and using them. Using its proprietary CRANE® platform, the company is developing a pipeline of “off-the-shelf” Treg cell product candidates designed to suppress pathological inflammation and support tissue repair and regeneration.
This press release contains forward-looking statements regarding the clinical development of CK0801. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
PARIS, April 27, 2026 /PRNewswire/ — A new study has established that treatment with essential phospholipids (Essentiale) resulted in a 2.5 times greater reduction in liver fat, significant improvement in fatigue and improvement of glycaemic control in individuals with Metabolic dysfunction–Associated Steatotic Liver Disease (MASLD) – also known as ‘Fatty Liver Disease’ – than diet and exercise alone.
The results were found by the EXCEL clinical trial from Essentiale (an Opella brand) – a multi-centre, randomized, double-blind, placebo-controlled study and the first of its kind to test essential phospholipids (EPLs). The study examined MASLD patients with comorbidities such as type 2 diabetes, hyperlipidaemia, or obesity.
MASLD is the most prevalent chronic liver disease worldwide, affecting an estimated 30% of the adult population, with projections indicating over 55% of adults worldwide will be affected by 2040[1].
Often considered a “silent” condition, fatty liver disease is frequently associated with a debilitating constellation of symptoms such as abdominal pain, fatigue, sleep issues, bloating, depressive symptoms, anxiety and metabolic risks.
Professor Norbert Stefan, Holder of the Chair of Clinical and Experimental Diabetology at the University of Tübingen. “This groundbreaking research marks an important moment for the millions of people currently living with MASLD. The EXCEL study underscores the clinical importance of early intervention and bridges the gap between scientific evidence and patient experience. By demonstrating measurable improvements in liver fat reduction and improvement of fatigue, this study reinforces the vital message that effective, evidence-based options exist to transform outcomes and restore hope for a more energized life in people with MASLD.”
The EXCEL study used modern, non-invasive imaging to measure liver fat alongside a validated, disease-specific questionnaire to assess the treatment’s impact on patient wellbeing. The main trial results showed that, when used in addition to diet and exercise, essential phospholipids were associated with:
A 2.5 times greater reduction in liver fat compared with lifestyle intervention alone, as measured by FibroScan CAP (Controlled Attenuation Parameter).
A statistically significant improvement in patient-reported fatigue, a primary and often overlooked symptom of MASLD. This outcome was formally assessed using the validated CLDQ-MASLD score, a standardized measure of well-being in individuals with chronic liver disease.
The study also noted that treatment with EPLs significantly reduced HbA1c levels, a key marker for glycemic control in patients with type 2 diabetes, making the findings particularly relevant for the large percentage of MASLD patients with co-existing metabolic conditions.
Nikunj Thakker Global Brand General Manager Essentiale, Opella. “The EXCEL study proves that timing is everything. When caught early, a significant portion of MASLD cases can be reversible. This evidence-based treatment, using essential phospholipids combined with diet and exercise, actively reduces liver fat and tackles debilitating fatigue head-on, changing outcomes for the billions globally living with Fatty Liver Disease.”
LONDON, April 27, 2026 /PRNewswire/ — Concept Medical Inc., today announced the presentation of preliminary 3-year follow-up data from the SIRONA randomised trial at the Charing Cross (CX) Symposium 2026, reinforcing its leadership in drug-delivery technologies for peripheral interventions.
Preliminary 3-Year SIRONA Data Presented at CX-2026 Demonstrates Durable Freedom from Reintervention with MagicTouch PTA in Femoropopliteal Disease
The data were presented by Principal Investigator Prof. Ulf Teichgräber during a podium first session on ‘3-year results from the SIRONA randomised trial.’
SIRONA is a randomised controlled trial evaluating sirolimus-coated versus paclitaxel-coated balloon angioplasty in femoropopliteal artery disease, designed to generate robust head-to-head comparative evidence in a field historically dominated by paclitaxel-based therapies. Previously in JACC published 12-month results demonstrated non-inferiority across the trial’s primary efficacy and safety endpoints.
In the current 3-year analysis, MagicTouch PTA, a sirolimus-coated balloon, showed higher freedom from clinically driven target lesion revascularization (cdTLR) compared with the paclitaxel-coated balloon group (88.2% vs 80.2%; HR 0.60; 95% CI 0.36–0.97; log-rank p=0.03). The results are pending Clinical Events Committee (CEC) adjudication. Taken together, these preliminary findings suggest that sirolimus-coated balloon angioplasty may provide more durable long-term outcomes than paclitaxel-coated balloon angioplasty.
At 3 years, Freedom of all-cause mortality remained comparable between treatment groups (92.6% vs 92.6%; HR 1.12; p=0.67), supporting a balanced long-term safety profile. Rates of Freedom of major amputation were low, with no statistically significant difference observed between groups (99.6% vs 99.6%;HR 0.54; p=0.61).
Prof. Ulf Teichgräber, Principal Investigator, said, “The preliminary 3-year SIRONA data are very exciting. Seeing a sustained reduced reduction in cdTLR with MagicTouch PTA over such a long follow-up period is highly encouraging and speaks to the durability of sirolimus-based drug delivery in femoropopliteal interventions. These findings add important long-term randomized evidence to the field and, pending final CEC adjudication, represent a very promising signal for the future role of sirolimus-coated balloons in peripheral artery disease. Importantly, these findings should not be interpreted as a class effect, but rather highlight the need to evaluate individual sirolimus-coated balloon technologies based on robust clinical evidence.”
Dr Manish Doshi, Founder and Managing Director, Concept Medical, added, “For us, SIRONA represents the discipline of long-term clinical science, going beyond early outcomes to truly understand durability. These 3-year findings continue to strengthen the comparative evidence for sirolimus-coated balloon therapy. As we scale globally, our focus remains on generating high-quality, long-term data that clinicians can rely on with confidence.”
About Concept Medical
Concept Medical Inc. is a global pioneer in drug-delivery technologies for vascular interventions. The company is headquartered in Florida, USA, with manufacturing operations in India. Its proprietary Nanolute™ technology platform is designed to enable controlled and sustained delivery of sirolimus across coronary and peripheral applications. The company’s flagship product, MagicTouch, is among the most clinically studied sirolimus-coated balloon platforms worldwide.
Source: Data from the SIRONA randomised trial, presented by Prof. Ulf Teichgräber at the Charing Cross (CX) Symposium 2026, London, UK. Preliminary results prior to Clinical Events Committee (CEC) adjudication.
BEIJING, April 27, 2026 /PRNewswire/ — All New GAC, Going Global! On April 24, at the Auto China 2026, GAC International held its first dedicated global launch event, unveiling an upgraded global strategy system. It also brought three key models destined for global markets – the GAC YUE7, AION i60, and AION N60 – drawing widespread attention. Approximately 330 attendees gathered at the GAC booth, including dealer representatives, key partners, and domestic and international media, to jointly open a new chapter in GAC’s global journey.
At the event, distinguished guests including Serge Gachot, CEO of Paris Motor Show Organizer; Ali Haydar Bozkurt, Representative of Jameel Motors; Mishari Aljomaih, Saudi Dealer Representative; Feng Xingya, Chairman of GAC Group; Jack Chen, Vice President of GAC Group and Chairman of GAC INTERNATIONAL; Li Yong, Chairman of GAC Business; Zhang Zhiyong, President of GAC New Energy Commercial Vehicle; Li Canhui, Vice President of GAC-Sofinco Auto Finance; and Wei Haigang, President of GAC INTERNATIONAL, among other leaders and guests, gathered to witness this momentous occasion.
Three Models Launched, Precisely Targeting Major Global Market Segments
As a critical step in executing the global strategy, the launch highlighted three key models destined for global markets – the GAC YUE7, AION i60, and AION N60.
The AION i60 is positioned as a “range-anxiety-free family car.” It is equipped with GAC’s new-generation GAC ADiMOTION series, with a CLTC combined range of up to 1,240 km, fundamentally relieving range anxiety. The model has already won two awards: “Top 10 REEV Models” and “Top 10 EV Models.” It will be officially launched globally at the end of this year.
From building partner consensus to releasing global guidelines, from new model debuts to ecosystem layout, GAC’s global strategy is rapidly turning from blueprint to reality. In the future, GAC will continue to work with global partners to enable consumers around the world to share in the progress of China’s technological achievements, jointly creating low-carbon, green, and intelligent mobility value for a better life.